Literature DB >> 25619503

Incremental value of secretin-enhanced magnetic resonance cholangiopancreatography in detecting ductal communication in a population with high prevalence of small pancreatic cysts.

Neda Rastegar1, Luciana G Matteoni-Athayde1, John Eng1, Naoki Takahashi2, Eric P Tamm3, Koenraad J Mortele4, Sapna Syngal5, Daniel Margolis6, Anne Marie Lennon1, Christopher L Wolfgang1, Elliot K Fishman1, Ralph H Hruban1, Michael Goggins1, Marcia I Canto1, Ihab R Kamel7.   

Abstract

PURPOSE: We investigated the incremental diagnostic yield of S-MRCP in a population with high prevalence of small pancreatic cysts.
METHODS: Standard MRCP protocol was performed with and without secretin using 1.5 T units in subjects undergoing pancreatic screening because of a strong family history of pancreatic cancer as part of the multicenter Cancer of the Pancreas Screening-3 trial (CAPS 3). All studies were reviewed prospectively by two independent readers who recorded the presence and number of pancreatic cysts, the presence of visualized ductal communication before and after secretin, and the degree of confidence in the diagnoses. RESULT: Of 202 individuals enrolled (mean age 56 years, 46% males), 93 (46%) had pancreatic cysts detected by MRCP, and 64 of the 93 had pre-and post-secretin MRCP images available for comparison. Data from the 128 readings show that 6 (6/128=4.7%) had ductal communication visualized only on the secretin studies compared to pre-secretin studies (odds ratio 1.28, p=0.04). In addition, there was a statistically significant increase in confidence in reporting ductal communication after secretin compared to before secretin (p<0.0005).
CONCLUSION: At 1.5 T MRI, the use of secretin can improve the visualization of ductal communication of cystic pancreatic lesions.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cyst; Magnetic resonance imaging; Neoplasm; Pancreas; Screening; Secretin

Mesh:

Substances:

Year:  2015        PMID: 25619503      PMCID: PMC5024538          DOI: 10.1016/j.ejrad.2014.12.028

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  27 in total

1.  Genetic susceptibility to pancreatic cancer.

Authors:  Alison P Klein
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

Review 2.  Secretin, 100 years later.

Authors:  William Y Chey; Ta-Min Chang
Journal:  J Gastroenterol       Date:  2003       Impact factor: 7.527

3.  Collateral branches IPMTs: secretin-enhanced MRCP.

Authors:  Giovanni Carbognin; Lucia Pinali; Veronica Girardi; Andrea Casarin; Giancarlo Mansueto; Roberto Pozzi Mucelli
Journal:  Abdom Imaging       Date:  2007 May-Jun

4.  Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics.

Authors:  Elizabeth C Verna; Caroline Hwang; Peter D Stevens; Heidrun Rotterdam; Stavros N Stavropoulos; Carolyn D Sy; Martin A Prince; Wendy K Chung; Robert L Fine; John A Chabot; Harold Frucht
Journal:  Clin Cancer Res       Date:  2010-09-28       Impact factor: 12.531

5.  Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer.

Authors:  T A Brentnall; M P Bronner; D R Byrd; R C Haggitt; M B Kimmey
Journal:  Ann Intern Med       Date:  1999-08-17       Impact factor: 25.391

6.  Frequent detection of pancreatic lesions in asymptomatic high-risk individuals.

Authors:  Marcia Irene Canto; Ralph H Hruban; Elliot K Fishman; Ihab R Kamel; Richard Schulick; Zhe Zhang; Mark Topazian; Naoki Takahashi; Joel Fletcher; Gloria Petersen; Alison P Klein; Jennifer Axilbund; Constance Griffin; Sapna Syngal; John R Saltzman; Koenraad J Mortele; Jeffrey Lee; Eric Tamm; Raghunandan Vikram; Priya Bhosale; Daniel Margolis; James Farrell; Michael Goggins
Journal:  Gastroenterology       Date:  2012-01-12       Impact factor: 22.682

7.  Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development.

Authors:  Jian Wu; Hanno Matthaei; Anirban Maitra; Marco Dal Molin; Laura D Wood; James R Eshleman; Michael Goggins; Marcia I Canto; Richard D Schulick; Barish H Edil; Christopher L Wolfgang; Alison P Klein; Luis A Diaz; Peter J Allen; C Max Schmidt; Kenneth W Kinzler; Nickolas Papadopoulos; Ralph H Hruban; Bert Vogelstein
Journal:  Sci Transl Med       Date:  2011-07-20       Impact factor: 17.956

8.  Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate?

Authors:  Roberto Salvia; Stefano Crippa; Massimo Falconi; Claudio Bassi; Alessandro Guarise; Aldo Scarpa; Paolo Pederzoli
Journal:  Gut       Date:  2006-11-24       Impact factor: 23.059

9.  The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer.

Authors:  J W Poley; I Kluijt; D J Gouma; F Harinck; A Wagner; C Aalfs; C H J van Eijck; A Cats; E J Kuipers; Y Nio; P Fockens; M J Bruno
Journal:  Am J Gastroenterol       Date:  2009-06-02       Impact factor: 10.864

10.  Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer.

Authors:  P Langer; P H Kann; V Fendrich; N Habbe; M Schneider; M Sina; E P Slater; J T Heverhagen; T M Gress; M Rothmund; D K Bartsch
Journal:  Gut       Date:  2009-05-25       Impact factor: 23.059

View more
  9 in total

1.  Active Surveillance Beyond 5 Years Is Required for Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms Undergoing Non-Operative Management.

Authors:  Stefano Crippa; Raffaele Pezzilli; Massimiliano Bissolati; Gabriele Capurso; Luigi Romano; Maria Paola Brunori; Lucia Calculli; Domenico Tamburrino; Alessandra Piccioli; Giacomo Ruffo; Gianfranco Delle Fave; Massimo Falconi
Journal:  Am J Gastroenterol       Date:  2017-02-28       Impact factor: 10.864

Review 2.  Surveillance for neoplasia in the pancreas.

Authors:  Kasper A Overbeek; Djuna L Cahen; Marcia Irene Canto; Marco J Bruno
Journal:  Best Pract Res Clin Gastroenterol       Date:  2016-11-05       Impact factor: 3.043

3.  Causal Evaluation of Acute Recurrent and Chronic Pancreatitis in Children: Consensus From the INSPPIRE Group.

Authors:  Cheryl E Gariepy; Melvin B Heyman; Mark E Lowe; John F Pohl; Steven L Werlin; Michael Wilschanski; Bradley Barth; Douglas S Fishman; Steven D Freedman; Matthew J Giefer; Tanja Gonska; Ryan Himes; Sohail Z Husain; Veronique D Morinville; Chee Y Ooi; Sarah J Schwarzenberg; David M Troendle; Elizabeth Yen; Aliye Uc
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-01       Impact factor: 2.839

Review 4.  State-of-the-Art Update of Pancreatic Cysts.

Authors:  Andrew Canakis; Linda S Lee
Journal:  Dig Dis Sci       Date:  2021-08-12       Impact factor: 3.487

Review 5.  ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts.

Authors:  Grace H Elta; Brintha K Enestvedt; Bryan G Sauer; Anne Marie Lennon
Journal:  Am J Gastroenterol       Date:  2018-02-27       Impact factor: 10.864

6.  Methods and outcomes of screening for pancreatic adenocarcinoma in high-risk individuals.

Authors:  Gabriele Capurso; Marianna Signoretti; Roberto Valente; Urban Arnelo; Matthias Lohr; Jan-Werner Poley; Gianfranco Delle Fave; Marco Del Chiaro
Journal:  World J Gastrointest Endosc       Date:  2015-07-25

7.  Comparison of endoscopic ultrasound, computed tomography and magnetic resonance imaging in assessment of detailed structures of pancreatic cystic neoplasms.

Authors:  Chen Du; Ning-Li Chai; En-Qiang Linghu; Hui-Kai Li; Li-Hua Sun; Lei Jiang; Xiang-Dong Wang; Ping Tang; Jing Yang
Journal:  World J Gastroenterol       Date:  2017-05-07       Impact factor: 5.742

Review 8.  Management of Intraductal Papillary Mucinous Neoplasms: Controversies in Guidelines and Future Perspectives.

Authors:  Ijm Levink; M J Bruno; D L Cahen
Journal:  Curr Treat Options Gastroenterol       Date:  2018-09

Review 9.  Secretin-stimulated MR cholangiopancreatography: spectrum of findings in pancreatic diseases.

Authors:  Piero Boraschi; Francescamaria Donati; Rosa Cervelli; Federica Pacciardi
Journal:  Insights Imaging       Date:  2016-09-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.